BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Browne CA, Lucki I. Targeting opioid dysregulation in depression for the development of novel therapeutics. Pharmacol Ther 2019;201:51-76. [PMID: 31051197 DOI: 10.1016/j.pharmthera.2019.04.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Neale KJ, Weimer MB, Davis MP, Jones KF, Kullgren JG, Kale SS, Childers J, Broglio K, Merlin JS, Peck S, Francis SY, Bango J, Jones CA, Sager Z, Ho JJ. Top Ten Tips Palliative Care Clinicians Should Know About Buprenorphine. J Palliat Med 2022. [PMID: 36067137 DOI: 10.1089/jpm.2022.0399] [Reference Citation Analysis]
2 Turan Yücel N, Evren AE, Kandemir Ü, Can ÖD. Antidepressant-like effect of tofisopam in mice: A behavioural, molecular docking and MD simulation study. J Psychopharmacol 2022;:2698811221095528. [PMID: 35638175 DOI: 10.1177/02698811221095528] [Reference Citation Analysis]
3 D'oliveira da Silva F, Azevedo Neto J, Sturaro C, Guarino A, Robert C, Gavioli EC, Calo G, Mouledous L, Ruzza C. The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109077] [Reference Citation Analysis]
4 Wulf HA, Browne CA, Zarate CA, Lucki I. Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors. Psychopharmacology (Berl) 2022. [PMID: 35459958 DOI: 10.1007/s00213-022-06118-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Jain N, Sharma M, Wang D, Ugiliweneza B, Drazin D, Boakye M. The Phenotypes of Anxiety and Depression: Analysis of Combined Comorbidity and Treatment in Patients Undergoing Spinal Fusion. Neurosurgery 2022. [PMID: 35377352 DOI: 10.1227/neu.0000000000001935] [Reference Citation Analysis]
6 Martins CC, Rosa SG, Zborowski VA, Rodrigues RF, Maroneze A, Nogueira CW, Zeni G. Contribution of Opioid and Nitrergic Systems to m-Trifluoromethyl diphenyl Diselenide Attenuates Morphine-Induced Tolerance in Mice. ACS Chem Neurosci 2022;13:910-9. [PMID: 35319862 DOI: 10.1021/acschemneuro.1c00691] [Reference Citation Analysis]
7 Smesam HN, Qazmooz HA, Khayoon SQ, Almulla AF, Al-hakeim HK, Maes M. Pathway Phenotypes Underpinning Depression, Anxiety, and Chronic Fatigue Symptoms Due to Acute Rheumatoid Arthritis: A Precision Nomothetic Psychiatry Analysis. JPM 2022;12:476. [DOI: 10.3390/jpm12030476] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Jarończyk M, Walory J. Novel Molecular Targets of Antidepressants. Molecules 2022;27:533. [PMID: 35056845 DOI: 10.3390/molecules27020533] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chen C, Ding H, Mabry KM, Ko M. Enhanced antidepressant-like effects of a delta opioid receptor agonist, SNC80, in rats under inflammatory pain. Pharmacology Biochemistry and Behavior 2022. [DOI: 10.1016/j.pbb.2022.173341] [Reference Citation Analysis]
10 Fillesoye F, Ibazizène M, Marie N, Noble F, Perrio C. Evaluation of Specific Binding of [11C]RTI-97 to Kappa Opioid Receptor by Autoradiography and PET Imaging in Rat. ACS Med Chem Lett 2021;12:1739-44. [PMID: 34795862 DOI: 10.1021/acsmedchemlett.1c00369] [Reference Citation Analysis]
11 Dmitrzak-Weglarz M, Szczepankiewicz A, Rybakowski J, Kapelski P, Bilska K, Skibinska M, Reszka E, Lesicka M, Jablonska E, Wieczorek E, Pawlak J. Expression Biomarkers of Pharmacological Treatment Outcomes in Women with Unipolar and Bipolar Depression. Pharmacopsychiatry 2021;54:261-8. [PMID: 34470067 DOI: 10.1055/a-1546-9483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhang F, Hillhouse TM, Anderson PM, Koppenhaver PO, Kegen TN, Manicka SG, Lane JT, Pottanat E, Van Fossen M, Rice R, Porter JH. Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice. Pharmacol Biochem Behav 2021;208:173228. [PMID: 34224734 DOI: 10.1016/j.pbb.2021.173228] [Reference Citation Analysis]
13 Zhuang T, Xiong J, Hao S, Du W, Liu Z, Liu B, Zhang G, Chen Y. Bifunctional μ opioid and σ1 receptor ligands as novel analgesics with reduced side effects. Eur J Med Chem 2021;223:113658. [PMID: 34175542 DOI: 10.1016/j.ejmech.2021.113658] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Mousa RF, Smesam HN, Qazmooz HA, Al-Hakeim HK, Maes M. A pathway phenotype linking metabolic, immune, oxidative, and opioid pathways with comorbid depression, atherosclerosis, and unstable angina. CNS Spectr 2021;:1-15. [PMID: 34039448 DOI: 10.1017/S1092852921000432] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Xia CY, He J, Du LD, Yan Y, Lian WW, Xu JK, Zhang WK. Targeting the dysfunction of glutamate receptors for the development of novel antidepressants. Pharmacol Ther 2021;226:107875. [PMID: 33901503 DOI: 10.1016/j.pharmthera.2021.107875] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Du Y, Wei J, Yang X, Dou Y, Zhao L, Qi X, Yu X, Guo W, Wang Q, Deng W, Li M, Lin D, Li T, Ma X. Plasma metabolites were associated with spatial working memory in major depressive disorder. Medicine (Baltimore) 2021;100:e24581. [PMID: 33663067 DOI: 10.1097/MD.0000000000024581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Wang HQ, Wang ZZ, Chen NH. The receptor hypothesis and the pathogenesis of depression: Genetic bases and biological correlates. Pharmacol Res 2021;167:105542. [PMID: 33711432 DOI: 10.1016/j.phrs.2021.105542] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
18 Chen M, Wu S, Shen B, Fan Q, Zhang R, Zhou Y, Zhang P, Wang L, Zhang L. Activation of the δ opioid receptor relieves cerebral ischemic injury in rats via EGFR transactivation. Life Sci 2021;273:119292. [PMID: 33667516 DOI: 10.1016/j.lfs.2021.119292] [Reference Citation Analysis]
19 Clark SD. The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach. Handb Exp Pharmacol 2022;271:525-46. [PMID: 33459877 DOI: 10.1007/164_2020_396] [Reference Citation Analysis]
20 Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. Mol Neurodegener 2021;16:2. [PMID: 33441154 DOI: 10.1186/s13024-021-00424-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
21 Schmidhammer H, Erli F, Guerrieri E, Spetea M. Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities. Molecules 2020;25:E5092. [PMID: 33147885 DOI: 10.3390/molecules25215092] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Huneke NTM, van der Wee N, Garner M, Baldwin DS. Why we need more research into the placebo response in psychiatry. Psychol Med 2020;50:2317-23. [PMID: 33028433 DOI: 10.1017/S0033291720003633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Jacobson ML, Wulf HA, Browne CA, Lucki I. The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice. Psychopharmacology (Berl) 2020;237:3715-28. [PMID: 32894343 DOI: 10.1007/s00213-020-05649-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Jacobson ML, Wulf HA, Tsuda MC, Browne CA, Lucki I. Sex differences in the modulation of mouse nest building behavior by kappa opioid receptor signaling. Neuropharmacology 2020;177:108254. [PMID: 32726598 DOI: 10.1016/j.neuropharm.2020.108254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
25 Page S, Mavrikaki MM, Lintz T, Puttick D, Roberts E, Rosen H, Carroll FI, Carlezon WA, Chartoff EH. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats. Int J Neuropsychopharmacol 2019;22:735-45. [PMID: 31613314 DOI: 10.1093/ijnp/pyz054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
26 Saad Z, Hibar D, Fedgchin M, Popova V, Furey ML, Singh JB, Kolb H, Drevets WC, Chen G. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials. Int J Neuropsychopharmacol 2020;23:549-58. [PMID: 32367114 DOI: 10.1093/ijnp/pyaa030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
27 Frank GKW. Pharmacotherapeutic strategies for the treatment of anorexia nervosa - too much for one drug? Expert Opin Pharmacother 2020;21:1045-58. [PMID: 32281881 DOI: 10.1080/14656566.2020.1748600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
28 Varastehmoradi B, Wegener G, Sanchez C, Smith KL. Opioid system modulation of cognitive affective bias: implications for the treatment of mood disorders. Behavioural Pharmacology 2020;31:122-35. [DOI: 10.1097/fbp.0000000000000559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
29 Madison CA, Eitan S. Buprenorphine: prospective novel therapy for depression and PTSD. Psychol Med 2020;50:881-93. [DOI: 10.1017/s0033291720000525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Browne CA, Smith T, Lucki I. Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression. Eur J Pharmacol 2020;872:172948. [PMID: 31991139 DOI: 10.1016/j.ejphar.2020.172948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Browne CA, Jacobson ML, Lucki I. Novel Targets to Treat Depression: Opioid-Based Therapeutics. Harv Rev Psychiatry 2020;28:40-59. [DOI: 10.1097/hrp.0000000000000242] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 5.5] [Reference Citation Analysis]
32 Nagase H, Saitoh A. Research and development of κ opioid receptor agonists and δ opioid receptor agonists. Pharmacol Ther 2020;205:107427. [PMID: 31654658 DOI: 10.1016/j.pharmthera.2019.107427] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
33 Shekhar A. Role of Kappa Opioid Receptors in Symptoms of Schizophrenia: What Is the Neurobiology? Biological Psychiatry 2019;86:494-6. [DOI: 10.1016/j.biopsych.2019.08.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]